ReviewCancers2023
A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Seroprevalence and Early Indicators of HBV and HCV Co-infection Among Newly Diagnosed HIV Patients: A Cross-Sectional Study from India.AIDS and behavior · 2026Article
- Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Nanomedicine (London, England) · 2026Article
- Integrative systems biology and transcriptomic database analysis (GEPIA2 and TNMplot) uncover HRAS-driven anticancer mechanisms of anthraquinones in liver cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Primary Cancer Prevention Through Vaccination: Advances, Challenges, and Global Perspectives.Health science reports · 2026Article
- Review
- Emerging and Prospective Engineering Technologies Enabling Microneedle Based Vaccine Therapeutics.AAPS PharmSciTech · 2026Review
- Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes.Microorganisms · 2026Review
- Food and nutrition literacy and diet self-efficacy among patients with liver cancer: latent profile analysis, associated factors, and an exploratory examination of gender differences.Frontiers in nutrition · 2026Article
- Global comorbidity of ischemic heart disease and liver cancer: an ecological analysis of shared risk factors.Annals of medicine and surgery (2012) · 2026Article
- The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer.International journal of molecular sciences · 2025Review
- The multi-kingdom cancer microbiome.Nature microbiology · 2025Review
- Circular RNAs in hepatitis B virus-induced hepatocellular carcinoma: A comprehensive review and recent advances.Genes & diseases · 2025Review
- A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT): Use of a Clinical Database Case-Finding Tool for Hepatitis B, Hepatitis C and HIV in Primary Care.Journal of viral hepatitis · 2025Article
- The interplay of socio-demographic factors and disease prevalence: insights into malaria, Hepatitis B, and Hepatitis C in Lafia, Nasarawa State, Nigeria.Journal of health, population, and nutrition · 2025Article
- Synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma in a single patient with chronic hepatitis B: two case reports and literature review.Frontiers in oncology · 2025Article
- LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis.PloS one · 2025Article
- PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review).International journal of oncology · 2024Review
- Impact of educational interventions on hepatitis B and C awareness among school students of Delhi NCR, India.BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading cause of hepatocellular carcinoma (HCC) worldwide. Currently, HBV-related HCC predominates in Sub-Saharan Africa and South-East-Asia, while HCV-related HCC predominates in northern Africa and in the western world. Liver cirrhosis is the underlying condition in most HBV cases and in nearly all HCV cases. Several cofactors, viral and non-viral, play a role in the progression toward HCC: dual HBV/HCV infection, HDV, HIV, alcohol intake, smoking, diabetes mellitus, obesity, and NAFLD/NASH. HBV vaccine is effective in preventing both infection and HCC; antiviral drugs may suppress HBV replication and eradicate HCV infection, halting progression to HCC. Inequalities exist between high- and low-income countries with respect to vaccine availability and access to antivirals. These factors represent barriers to the control of HCC incidence. Lack of an effective vaccine against HCV is also a serious barrier to HCV elimination and HCC prevention. The most crucial steps and knowledge that have arisen over time on the association between the two major hepatotropic viruses and HCC are discussed in this historical review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.